Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).

@article{Capuano2015MineralocorticoidRA,
  title={Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).},
  author={Annalisa Capuano and Cristina Scavone and Cristiana Vitale and Liberata Sportiello and Francesco Rossi and Giuseppe M C Rosano and Andrew J. S. Coats},
  journal={International journal of cardiology},
  year={2015},
  volume={200},
  pages={
          15-9
        }
}
View on PubMed
doi.org
14 Citations
Background Citations
5

Tables from this paper

14 Citations

Role of spironolactone in the treatment of heart failure with preserved ejection fraction.
TLDR
This review aims to present and discuss the clinical and scientific data pertaining to the role of spironolactone in the treatment of patients with HFpEF.
Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
This study aims to investigate the prognostic impact of mineralocorticoid receptor antagonists (MRAs) on cardiovascular events in patients hospitalized for acute decompensated heart failure with…
Spironolactone inhibits endothelial-mesenchymal transition via the adenosine A2A receptor to reduce cardiorenal fibrosis in rats.
MicroRNA and Heart Failure
TLDR
An overview of the role of mi RNAs in the cardiovascular system is provided and several HF-related miRNAs reported from selected cohorts are highlighted and their putative roles in neurohormonal signaling are reviewed.
The role of oxidative stress in the crosstalk between leptin and mineralocorticoid receptor in the cardiac fibrosis associated with obesity
TLDR
A role of mineralocorticoid receptor in the cardiac fibrosis induced by leptin in the context of obesity is supported and the role of the mitochondrial ROS in this process is highlighted.
Reversing Cardiac Hypertrophy at the Source Using a Cardiac Targeting Peptide Linked to miRNA106a: Targeting Genes That Cause Cardiac Hypertrophy
TLDR
It is shown that miRNA106a targets genes that, when misregulated, have been shown to cause hypertrophy and eventual HF and delivery is specific to cardiomyocytes.
New and old roles of the peripheral and brain renin-angiotensin-aldosterone system (RAAS): Focus on cardiovascular and neurological diseases.
Diverse origins and activation of fibroblasts in cardiac fibrosis.
Terapia opornego nadciśnienia tętniczego — badanie PATHWAY-2, czyli spironolakton kontratakuje
Nadciśnienie tetnicze definiuje sie jako oporne, gdy terapia oparta na diuretyku i dwoch innych lekach, nalezących do roznych klas lekow hipotensyjnych, nie prowadzi do obnizenia ciśnienia tetniczego…
Current and future therapeutic perspective in chronic heart failure
...
...

References

SHOWING 1-10 OF 32 REFERENCES
Spironolactone for heart failure with preserved ejection fraction.
TLDR
In patients with heart failure and a preserved ejection fraction, treatment with spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure.
Eplerenone in patients with systolic heart failure and mild symptoms.
TLDR
Eplerenone, as compared with placebo, reduced both the risk of death and therisk of hospitalization among patients with systolic heart failure and mild symptoms.
Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction.
Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF).
Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
TLDR
In this randomized controlled trial, long-term aldosterone receptor blockade improved left ventricular diastolic function but did not affect maximal exercise capacity, patient symptoms, or quality of life in patients with heart failure with preserved ejection fraction.
Current challenges in the management of heart failure.
  • M. Komajda
  • Medicine
    Circulation journal : official journal of the Japanese Circulation Society
  • 2015
TLDR
Heterogeneity of the populations tested, role of comorbidities, difficulties in identifying patients with HFpEF, as well as a mismatch between the clinical phenotypes and the treatments tested, can explain the failure to find beneficial interventions.
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
TLDR
The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction.
Pharmacotherapy of Heart Failure with Preserved Ejection Fraction
TLDR
Treatment of heart failure with preserved ejection fraction can be simplified by using three strategies based on applicability: treat precipitating conditions (e.g., hypertension, AF), control symptoms by maintaining euvolemia with diuretics, and avoid therapies that have been shown not to be beneficial unless another compelling indication exists.
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
...
...